Cjc 1295 Dac vs No Dac
Which Is Right for You? Complete Comparison (2026)
CJC-1295 DAC vs No DAC — what actually differs, which to choose, and why vendors confuse the two.
Cjc 1295 Dac vs No Dac: At a Glance
- ✓Modified GHRH(1-29) with Drug Affinity Complex (DAC)
- ✓DAC binds albumin → extends half-life to ~8 days
- ✓Produces sustained, continuous GH and IGF-1 elevation
- ✓Once or twice weekly dosing sufficient
- ✓Continuous GH pulse (not pulsatile like natural secretion)
- ✓Modified GHRH(1-29) without Drug Affinity Complex
- ✓Short half-life (~30 min) — mimics natural GH pulsatility
- ✓Must be dosed 2-3x daily for effect
- ✓Produces cleaner, more physiological GH pulses
- ✓Often stacked with GHRP (e.g., Ipamorelin) for synergy
Detailed Comparison
| Feature | Cjc 1295 Dac | No Dac |
|---|---|---|
| Mechanism | GHRH analogue with Drug Affinity Complex | GHRH analogue without DAC (short-acting)Best |
| Dosing | 2 mg SC once or twice weekly | 100 mcg SC 2-3x daily (often before bed) |
| Administration | Subcutaneous injection | Subcutaneous injection |
| Half-life | ~8 days (due to DAC albumin binding) | ~30 minutes |
| FDA Status | Not FDA-approved — research peptide | Not FDA-approved — research peptide |
| Key Trial | Teichman SL et al. JCEM 2006 — sustained GH/IGF-1 elevation | Teichman SL et al. JCEM 2006 — GHRH analogue characterization |
| Side Effects | Flushing, headache, water retention, injection site reactions | Flushing, headache, dizziness — generally mild |
Which Should You Choose?
CJC-1295 with DAC (ghrh analogue with drug affinity complex) and CJC-1295 without DAC (Mod GRF 1-29) (ghrh analogue without dac (short-acting)) target different aspects of health despite overlapping interest areas. CJC-1295 with DAC modified ghrh(1-29) analogue conjugated with drug affinity complex (dac) that binds albumin, extending half-life to ~8 days for sustained gh elevation. CJC-1295 without DAC (Mod GRF 1-29) modified ghrh(1-29) analogue without dac that produces natural pulsatile gh release with a short half-life of ~30 minutes.
Whichever you choose, track your protocol in Shotlee to build clean data for dose optimization and outcomes comparison.
Making an Informed Choice Between Cjc 1295 Dac and No Dac
Choosing between Cjc 1295 Dac and No Dac depends on multiple individual factors including your specific health goals, tolerance profile, insurance coverage, and prescriber recommendation. While clinical trial data provides population-level efficacy and safety comparisons, your personal response may differ based on genetics, baseline health, concurrent conditions, and lifestyle factors. Use this comparison as a starting framework and discuss the specifics with your healthcare provider.
Head-to-head clinical trial data between Cjc 1295 Dac and No Dac is the gold standard for comparison, but such direct comparisons are not always available for every pair of compounds. Where head-to-head data is lacking, cross-trial comparisons provide useful but imperfect approximations — differences in patient populations, trial design, and endpoint definitions mean that numbers from separate trials are not directly interchangeable. Keep this context in mind when evaluating the comparison data presented here.
Tracking your personal response data in Shotlee is particularly valuable when switching between medications or considering a change. By documenting your outcomes on your current protocol — including efficacy metrics, side effect profile, adherence rate, and quality of life measures — you create an objective baseline for comparison if you transition to the alternative compound. This data transforms a subjective switching decision into an evidence-based protocol optimization.
Cjc 1295 Dac vs No Dac: Frequently Asked Questions
CJC-1295 with DAC is a ghrh analogue with drug affinity complex while CJC-1295 without DAC (Mod GRF 1-29) is a ghrh analogue without dac (short-acting). They differ in mechanism, dosing, and clinical evidence. Your choice should depend on your specific goals and medical history.
Switching should be done under medical supervision. Your prescriber can advise on transition protocols. Track both in Shotlee for comparison data.
CJC-1295 with DAC works as a ghrh analogue with drug affinity complex (2 mg SC once or twice weekly), while CJC-1295 without DAC (Mod GRF 1-29) is a ghrh analogue without dac (short-acting) (100 mcg SC 2-3x daily (often before bed)). They have different half-lives (~8 days (due to DAC albumin binding) vs ~30 minutes), side effect profiles, and levels of clinical evidence.
Yes. Shotlee supports tracking any medication or peptide. You can compare your results across different protocols.
Neither is universally better — the right choice depends on your individual health profile, treatment goals, side effect tolerance, insurance coverage, and prescriber recommendation. Clinical trial data shows efficacy differences in specific populations, but personal response varies. Track your experience with either medication in Shotlee to generate objective comparison data with your healthcare provider.
Switching between these medications should be done under medical supervision. Your prescriber will consider factors including your current response, reason for switching, dose equivalence, and transition timing. Use Shotlee to document your outcomes on the current medication so you have a clear baseline for comparison after switching.
Track Cjc 1295 Dac or No Dac in Shotlee
Free dose tracking, side effect logging, and outcome comparison for any medication protocol.